Grace Therapeutics (GRCE) announced details of the Company’s Type C meeting with the U.S. Food and Drug Administration. The purpose of this meeting was to obtain FDA feedback on the completed Phase 3 STRIVE-ON safety trial of GTx-104 and its planned New Drug Application submission including clinical, non-clinical, and chemistry, manufacturing, and control requirements. Based on feedback from the FDA, the Company believes that the data and regulatory packages as currently structured will be sufficient for submission of an NDA.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRCE:
- Grace Therapeutics Reports Q3 Progress and Financial Results
- Grace Therapeutics Files Form S-3 for Flexible Securities Offering
- Grace Therapeutics files to sell 8.84M shares of common stock for holders
- Promising Potential of Grace Therapeutics’ GTX-104 Drives Buy Rating
- Grace Therapeutics reports Q3 EPS (36c), consensus (46c)